Congenital and Childhood myeloproliferative disorders with eosinophilia responsive to imatinib

Shirley Abraham, Mohamed Salama, Jeffrey Hancock, Jeffrey Jacobsen, Mark Fluchel

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Eosinophilia is seen in several myeloproliferative disorders (MPD). A subset of MPD involves the platelet-derived growth factor receptor beta (PDGFRB) gene. Imatinib mesylate has been efficacious in treating some of these MPDs. Here we describe two patients with MPD with eosinophilia and PDGFRB rearrangements, one of which was congenital. Both patients were treated with single agent imatinib and continue to be in clinical, hematologic, and cytogenetic remission despite weaning doses. No definite guidelines currently exist regarding the exact dosing and duration of imatinib therapy for these patients.

Original languageEnglish (US)
Pages (from-to)928-929
Number of pages2
JournalPediatric Blood and Cancer
Volume59
Issue number5
DOIs
StatePublished - Nov 1 2012

Keywords

  • Imatinib
  • Myeloproliferative disorders
  • PGFRB

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Congenital and Childhood myeloproliferative disorders with eosinophilia responsive to imatinib'. Together they form a unique fingerprint.

  • Cite this